Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Begrivac (2007/2008) in Adults and Elderly
NCT00498303Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Agrippal S1 in influenza, sponsored by Novartis. Primary endpoints: Antibody response to each influenza vaccine antigen as measured by haemagglutination inhibition (HI) test at Day 21 and Safety of trivalent split influenza vaccine. Started Jun 2007; status: completed.
02
Drugs
Agrippal S1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00498303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498303.